<DOC>
	<DOCNO>NCT01555125</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy secukinumab Week 12 base PASI IGA response rate versus placebo subject moderate severe chronic plaque-type psoriasis .</brief_summary>
	<brief_title>First Study Secukinumab Pre-filled Syringes Subjects With Chronic Plaque-type Psoriasis : Response 12 Weeks</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Moderate severe plaquetype psoriasis diagnose least 6 month . Severity psoriasis disease meeting follow three criterion : Psoriasis Area Severity Index ( PASI ) score 12 great , Investigator 's Global Assessment ( IGA ) score 3 great , Total body surface area ( BSA ) affect 10 % great . Inadequate control prior use topical treatment , phototherapy and/or systemic therapy . Exclusion criterion : Current form psoriasis chronic plaquetype psoriasis ( example , pustular , erythrodermic , guttate ) . Current druginduced psoriasis . Previous use secukinumab drug target IL17 IL17 receptor . Significant medical problem uncontrolled hypertension , congestive heart failure condition significantly immunocompromises subject . Hematological abnormality . History ongoing , chronic recurrent infectious disease , evidence untreated tuberculosis . History lymphoproliferative disease history malignancy organ system within past 5 year . Pregnant nursing ( lactate ) woman . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>